Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
Ahead of Market: 10 things that will decide stock market action on Monday
Sensex and Nifty ended last week lower amid range-bound trading, with broader markets also under pressure. Analysts identified four key factors that could drive Dalal
August 16, 2026